The COVID-19 pandemic has increased the demand for infrastructure in developing and manufacturing monoclonal antibody drugs and products that require mammalian cell bioreactor technologies.

Under the agreement, Yokogawa will leverage ICQ services to launch its new bioprocess technologies in the U.S., including its advanced control bioreactor system (BR1000). The company's bioreactor automates glucose control through in-line sensing, model predictive control software, and automated feed.

Aizon launches bioreactor application for analysis and insights
Aizon has launched its Aizon Bioreactor Application, a predictive analysis and deep knowledge management application. The technology will allow pharmaceutical...

KBI Biopharma expands cell-based manufacturing with new NC facility
KBI Biopharma, a biopharmaceutical contract service organization, has established a new commercial manufacturing facility in Research Triangle Park, NC....

Kriya establishes internal gene therapy manufacturing capacity
Kriya Therapeutics has secured a 51,000-sq-ft facility in Research Triangle Park, NC, to establish internal operational manufacturing of its pipeline...

Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp...